

Formulary Update

May 2026

The following changes to the [Adult Medicines Formulary](#) have been agreed during the ADTC or sub-committee meetings since March 2026. Additions and deletions of medicines are based on submitted formulary appeals, new drug assessment requests and formulary housekeeping exercises. Changes in preferred brands are based on decisions by Prescribing Management Groups.

ADTC decisions relating to SMC assessments are published in alternate months and can be accessed [here](#)

Deletions	Indication	Adult Medicines Formulary entry/ rationale	
Apraclonidine 0.5%	short-term treatment (typically up to one month) for chronic glaucoma when other medications fail to reduce eye pressure sufficiently.	11.8.2	discontinued
Azapropazone	Gout	10.1.4	discontinued
Botulinum toxin B	Treatment of cervical dystonia	4.9.3	discontinued
Conestat alfa	Hereditary angioedema	3.4.3	marketing authorisation withdrawn
Cyclimorph	Opioid analgesia	4.7.2	discontinued
Edrophonium	Short-acting diagnostic agent/ reversal of neuromuscular blockade	10.2.1	discontinued
Ethinylestradiol/ etonorgestrel vaginal ring	Monophasic low-strength combined oral contraceptives	7.3.1.1	SyreniRing now discontinued
Gemeprost	Medical termination of pregnancy	7.1.1.1	discontinued
Inotersen	Stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (hATTR)	4.9.4	Marketing Authorisation has been cancelled
Lofexidine	Opioid dependence	4.10.3	discontinued
Miconazole vaginal cream	Vaginal thrush	7.2.2	Gyno-Daktarin discontinued
Nystatin vaginal cream/pessaries	Vaginal thrush	7.2.2	Formulations discontinued
Pergolide	Parkinson's disease	4.9	discontinued
Sodium aurothiomalate	DMARD	10.1.3	No longer on NPT list
Sotrovimab	Covid-19 treatment	5.6	Manufacturer has discontinued manufacturing, supply, distribution and marketing in the UK
Vardenafil orodispersible tablets	Erectile dysfunction	7.4.5	Formulation discontinued

Additions	Indication	Adult Medicines Formulary entry/ rationale	
Changes in preferred medicines or brand	New preferred medicines or brand	Adult Medicines Formulary entry / rationale	
Other changes	Changes made	Adult Medicines Formulary entry/ rationale	
cladribine	Brand name removed	8.2.5	Available generically
Dapagliflozin/metformin	Brand name removed	6.1.2.2	Available generically
Droperidol	Brand name removed	4.6	Available generically
Eslicarbazepine	Brand name removed	4.8.1	Available generically
Fosaprepitant	Brand name removed	4.6	Available generically
Gilteritinib	Brand name removed	8.1.5	Available generically
Golimumab	Brand name removed	10.1.3	Available generically
Mexiletine	Brand name removed	10.2.3	Available generically
Mirabegron	Brand name removed	7.4.2	Available generically
Oxacarbazine	Brand name removed	4.8.1	Available generically
Relugolix	Brand name removed	8.3.4.2	Available generically
Solifenacin/tamsulosin	Brand name removed	7.4	Available generically
Ustekinumab	Brand name removed	10.1.3	Available generically